Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | B3 | Healthcare | Biotechnology & Medical Research | R$184.10B | -68.1x | -1.65 | R$61.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings BDR | B3 | Healthcare | Biotechnology & Medical Research | R$156.60B | 22x | 81.32 | R$212.96 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | B3 | Healthcare | Biotechnology & Medical Research | R$152.36B | -30.3x | 0.04 | R$38.92 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | B3 | Healthcare | Biotechnology & Medical Research | R$59.50B | -24.6x | -0.78 | R$63.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioTechne | B3 | Healthcare | Biotechnology & Medical Research | R$46.35B | 63.8x | -1.84 | R$9.96 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomm On | B3 | Healthcare | Biotechnology & Medical Research | R$951.31M | -13x | -0.39 | R$7.50 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |